Global Tissue and Organ Transplantation 麻豆原创 Research Report 2023

Publication ID:

PB510231881

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Chronic diseases often lead to catastrophic damage to vital organs. This damage is usually irreversible and leads to lifetime dependency on medicines. Under such severe conditions, transplants remain the component for restoration of healthy life.
The global Tissue and Organ Transplantation market is projected to reach US$ 24490 million in 2029, increasing from US$ 13860 million in 2022, with the CAGR of 8.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tissue and Organ Transplantation market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tissue and Organ Transplantation market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Discovery Life Sciences
Arthrex
Abbvie
Zimmer Biomet
Medtronic
Novartis
Stryker Corporation
Biolife Solutions
Teva Pharmaceuticals
Veloxis Pharmaceutical
Segment by Type
Tissue Products
Preservation Solution
Immunosuppressive Drugs
Segment by Application
Hospital
Transplant Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Tissue and Organ Transplantation report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Tissue and Organ Transplantation 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tissue Products
1.2.3 Preservation Solution
1.2.4 Immunosuppressive Drugs
1.3 麻豆原创 by Application
1.3.1 Global Tissue and Organ Transplantation 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Transplant Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tissue and Organ Transplantation 麻豆原创 Perspective (2018-2029)
2.2 Tissue and Organ Transplantation Growth Trends by Region
2.2.1 Global Tissue and Organ Transplantation 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tissue and Organ Transplantation Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Tissue and Organ Transplantation Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Tissue and Organ Transplantation 麻豆原创 Dynamics
2.3.1 Tissue and Organ Transplantation Industry Trends
2.3.2 Tissue and Organ Transplantation 麻豆原创 Drivers
2.3.3 Tissue and Organ Transplantation 麻豆原创 Challenges
2.3.4 Tissue and Organ Transplantation 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tissue and Organ Transplantation Players by Revenue
3.1.1 Global Top Tissue and Organ Transplantation Players by Revenue (2018-2023)
3.1.2 Global Tissue and Organ Transplantation Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Tissue and Organ Transplantation 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tissue and Organ Transplantation Revenue
3.4 Global Tissue and Organ Transplantation 麻豆原创 Concentration Ratio
3.4.1 Global Tissue and Organ Transplantation 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tissue and Organ Transplantation Revenue in 2022
3.5 Tissue and Organ Transplantation Key Players Head office and Area Served
3.6 Key Players Tissue and Organ Transplantation Product Solution and Service
3.7 Date of Enter into Tissue and Organ Transplantation 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Tissue and Organ Transplantation Breakdown Data by Type
4.1 Global Tissue and Organ Transplantation Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Tissue and Organ Transplantation Forecasted 麻豆原创 Size by Type (2024-2029)
5 Tissue and Organ Transplantation Breakdown Data by Application
5.1 Global Tissue and Organ Transplantation Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Tissue and Organ Transplantation Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Tissue and Organ Transplantation 麻豆原创 Size (2018-2029)
6.2 North America Tissue and Organ Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tissue and Organ Transplantation 麻豆原创 Size by Country (2018-2023)
6.4 North America Tissue and Organ Transplantation 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tissue and Organ Transplantation 麻豆原创 Size (2018-2029)
7.2 Europe Tissue and Organ Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tissue and Organ Transplantation 麻豆原创 Size by Country (2018-2023)
7.4 Europe Tissue and Organ Transplantation 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tissue and Organ Transplantation 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Tissue and Organ Transplantation 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tissue and Organ Transplantation 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Tissue and Organ Transplantation 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tissue and Organ Transplantation 麻豆原创 Size (2018-2029)
9.2 Latin America Tissue and Organ Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tissue and Organ Transplantation 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Tissue and Organ Transplantation 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tissue and Organ Transplantation 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Tissue and Organ Transplantation 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tissue and Organ Transplantation 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Tissue and Organ Transplantation 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Discovery Life Sciences
11.1.1 Discovery Life Sciences Company Detail
11.1.2 Discovery Life Sciences Business Overview
11.1.3 Discovery Life Sciences Tissue and Organ Transplantation Introduction
11.1.4 Discovery Life Sciences Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.1.5 Discovery Life Sciences Recent Development
11.2 Arthrex
11.2.1 Arthrex Company Detail
11.2.2 Arthrex Business Overview
11.2.3 Arthrex Tissue and Organ Transplantation Introduction
11.2.4 Arthrex Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.2.5 Arthrex Recent Development
11.3 Abbvie
11.3.1 Abbvie Company Detail
11.3.2 Abbvie Business Overview
11.3.3 Abbvie Tissue and Organ Transplantation Introduction
11.3.4 Abbvie Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.3.5 Abbvie Recent Development
11.4 Zimmer Biomet
11.4.1 Zimmer Biomet Company Detail
11.4.2 Zimmer Biomet Business Overview
11.4.3 Zimmer Biomet Tissue and Organ Transplantation Introduction
11.4.4 Zimmer Biomet Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.4.5 Zimmer Biomet Recent Development
11.5 Medtronic
11.5.1 Medtronic Company Detail
11.5.2 Medtronic Business Overview
11.5.3 Medtronic Tissue and Organ Transplantation Introduction
11.5.4 Medtronic Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.5.5 Medtronic Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Tissue and Organ Transplantation Introduction
11.6.4 Novartis Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Stryker Corporation
11.7.1 Stryker Corporation Company Detail
11.7.2 Stryker Corporation Business Overview
11.7.3 Stryker Corporation Tissue and Organ Transplantation Introduction
11.7.4 Stryker Corporation Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.7.5 Stryker Corporation Recent Development
11.8 Biolife Solutions
11.8.1 Biolife Solutions Company Detail
11.8.2 Biolife Solutions Business Overview
11.8.3 Biolife Solutions Tissue and Organ Transplantation Introduction
11.8.4 Biolife Solutions Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.8.5 Biolife Solutions Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Detail
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals Tissue and Organ Transplantation Introduction
11.9.4 Teva Pharmaceuticals Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Veloxis Pharmaceutical
11.10.1 Veloxis Pharmaceutical Company Detail
11.10.2 Veloxis Pharmaceutical Business Overview
11.10.3 Veloxis Pharmaceutical Tissue and Organ Transplantation Introduction
11.10.4 Veloxis Pharmaceutical Revenue in Tissue and Organ Transplantation Business (2018-2023)
11.10.5 Veloxis Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Discovery Life Sciences
Arthrex
Abbvie
Zimmer Biomet
Medtronic
Novartis
Stryker Corporation
Biolife Solutions
Teva Pharmaceuticals
Veloxis Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.